Search Results

The Quantase Phe/Gal Screening Assay is an eazymatic colorinetic cast-point mechod for the decired blood more maciment I he Quantist Parcelling Possy is an enzintate e. siactose-1-phosphate) in dried blood spot specimens taken from newborn human infants as part of a newborn screening programme The test is intended as a screening method for measuring the L-phenylalanine and total D(+)galactose I he ust is miched is a screening meason for messaring are not diagnostic per se of phenylkstomuria or galactosemia, but indicate the urgent need for further study of the newborn from which the presumptive positive specimen was received. The lit is NOT intended for use in monitoring the circulating concentrations of L-phenylalanine and total I be an is NOT measurer and galactosenic patients respectively, nor to detect ante-natal phenylketonucia and galactosemia or maternal phenylketonuria

Not Found

The perfect answer would include all the information listed in the prompt. However, based on the input provided, I cannot answer all parts fully. Here's a breakdown of what can and cannot be answered:

Information that CANNOT be extracted from the provided text:

• A table of acceptance criteria and the reported device performance: The document is a 510(k) clearance letter, not a study report. It does not contain acceptance criteria or performance data.
• Sample size used for the test set and the data provenance: Not mentioned in the provided text.
• Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not mentioned.
• Adjudication method: Not mentioned.
• If a multi-reader multi-case (MRMC) comparative effectiveness study was done, and the effect size: Not mentioned, as this is a diagnostic assay, not an imaging AI.
• If a standalone (i.e., algorithm only without human-in-the-loop performance) was done: While the device is a screening assay performed in a lab, the concept of "standalone performance" as it applies to an AI algorithm is not directly applicable or discussed in this context.
• The type of ground truth used: Not mentioned.
• The sample size for the training set: Not mentioned.
• How the ground truth for the training set was established: Not mentioned.

Information that CAN be extracted and inferred:

This document is primarily a 510(k) clearance letter for an in-vitro diagnostic device, specifically the "Quantase™ PHE/GAL Screening Assay." It confirms that the FDA has determined the device is substantially equivalent to legally marketed predicate devices. This type of document typically does not include detailed study results, acceptance criteria, or ground truth methodologies for the device's validation. Those details would be found in the original 510(k) submission and supporting documentation, which is not provided here.

Ask a specific question about this device